4 completed, 3 recruiting, 2 terminated, 1 withdrawn. 10 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 4, Recruiting 3, Terminated 2, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Persistent Corneal Epithelial Defect: new trials by email Literature Review of Persistent Corneal Epithelial Defect trials Research Report on Persistent Corneal Epithelial Defect
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of TP-06 for PCED TP-06, Vehicle of TP-06 - Persistent Corneal Epithelial Defect | Phase 2 | Recruiting | Tarsus Pharmaceuticals, Inc. | 32 | 2026-04-20 | 2026-10-21 |
| Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control - Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders | Phase 2 | Recruiting | University of Illinois Chicago | 24 | 2025-08-01 | 2026-10-28 |
| A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED lufepirsen high dose, Vehicle, lufepirsen low dose - Persistent Corneal Epithelial Defect | Phase 2 | Recruiting | Glaukos Corporation | 84 | 2023-08-17 | 2025-07-24 |
| Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED KPI-012, KPI-012 Vehicle - Persistent Corneal Epithelial Defect | Phase 2 | Terminated | Combangio, Inc | 103 | 2023-02-07 | 2025-10-22 |
| A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) - Persistent Corneal Epithelial Defect | Phase 2 | Completed | Kiora Pharmaceuticals, Inc. | 10 | 2022-07-01 | 2024-04-03 |
| ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects ST266, 0.67% Sodium Chloride Ophthalmic Solution, Open-label ST266 - Persistent Corneal Epithelial Defect | Phase 2 | Terminated | Noveome Biotherapeutics, formerly Stemnion | 8 | 2022-04-27 | 2022-10-25 |
| Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Trophic Ulcers LV-Visio-AMTRIX - Corneal Ulcer, Persistent Corneal Epithelial Defect | Phase 2 | Withdrawn | TBF Genie Tissulaire | 2022-04-01 | 2022-08-05 | |
| ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects ST266 - Persistent Corneal Epithelial Defect | Phase 2 | Completed | Noveome Biotherapeutics, formerly Stemnion | 13 | 2019-06-10 | 2021-08-18 |
| Autologous Platelet Lysate in Corneal Epithelial Defects Platelet Lysate - Persistent Corneal Epithelial Defect | Phase 1 / Phase 2 | Completed | Hanan Jafar | 10 | 2017-02-16 | 2021-03-03 |
| Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect DE-105 ophthalmic solution, Placebo ophthalmic solution - Persistent Corneal Epithelial Defect | Phase 2 | Completed | Santen Pharmaceutical Co., Ltd. | 45 | 2009-09-01 | 2012-11-22 |
Corneal Ulcer (1) · Limbal Stem Cell Deficiency (1)
Corneal Diseases (2) · Eye Diseases (2) · Eye Infections (1) · Infections (1) · Keratitis (1)
Noveome Biotherapeutics, formerly Stemnion (2) · Combangio, Inc (1) · Glaukos Corporation (1) · Hanan Jafar (1) · Kiora Pharmaceuticals, Inc. (1) · Santen Pharmaceutical Co., Ltd. (1) · TBF Genie Tissulaire (1) · Tarsus Pharmaceuticals, Inc. (1) · University of Illinois Chicago (1)
United States (6) · Mexico (2) · Argentina (1) · Dominican Republic (1) · El Salvador (1) · Germany (1) · Italy (1) · Japan (1) · Jordan (1) · Puerto Rico (1) · Spain (1)
Abdallah Awidi, MD (1) · Ali R Djalilian, MD (1) · Enrique Graue, M.D. (1) · Kristie Veasey (1) · Luis G. Vargas, MD (1)
3UH3EY031809-04S1 (1)